# Alpha-emitting PSMA therapy at first metastatic diagnosis

Source: https://nuclide.cc/ideas/idea-alpha-first-mhspc/  
Nuclide record `idea-alpha-first-mhspc` (Idea). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

If Pluvicto helps at first diagnosis, an alpha version might do more against microscopic disease, when tumour burden is smallest.

## Summary

This speculative idea would give alpha-emitting PSMA therapy with actinium-225 at the first metastatic diagnosis of hormone-sensitive prostate cancer, alongside hormone therapy. Short-range alpha emission suits small-volume disease and is oxygen-independent, and early treatment avoids the PSMA heterogeneity of castration resistance; PSMAddition established beta-emitter therapy here. The hypothesis is deeper PSA nadirs and longer radiographic progression-free survival than lutetium-177 PSMA-617 at equal or lower salivary dose; salivary toxicity and actinium-225 supply are limiting. The test is a randomised phase 2 with PSMA PET-based dosimetry, salivary gland protection and the undetectable-PSA rate at one year as primary endpoint.

## Fields

- Kind: Idea
- Last checked: 2026-09-06
- Hypothesis: 225Ac-PSMA added to ADT + ARPI in high-volume de novo mHSPC produces deeper PSA nadirs and longer rPFS than 177Lu-PSMA-617 at equal or lower cumulative salivary dose.
- Rationale: Short-range alpha emission suits small-volume disease; early treatment avoids PSMA heterogeneity that develops under castration resistance.
- Proposed test: Phase 2 randomised 225Ac-PSMA vs 177Lu-PSMA-617 in mHSPC with PSMA PET-based dosimetry, salivary gland protection, and undetectable-PSA rate at 12 months as primary.
- Maturity: speculative

## Sources

- ClinicalTrials.gov NCT04720157: PSMAddition: https://clinicaltrials.gov/study/NCT04720157

## Connected records

- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/), [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- indications: [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/), [Targeted alpha therapy](https://nuclide.cc/technologies/targeted-alpha-therapy/)
- drugs: [Actinium-225 PSMA agents](https://nuclide.cc/drugs/ac225-psma/), [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/)
- terms: [Alpha vs beta emitters](https://nuclide.cc/terms/alpha-vs-beta/), [Dosimetry](https://nuclide.cc/terms/dosimetry/)
- trials: [PSMAddition](https://nuclide.cc/trials/psmaddition/)
- roadmaps: [Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline](https://nuclide.cc/roadmaps/alpha-therapy-roadmap/), [PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha](https://nuclide.cc/roadmaps/psma-theranostics-roadmap/)

---
JSON: https://nuclide.cc/api/v1/entities/idea-alpha-first-mhspc.json